NCT05316818View on ClinicalTrials.gov

Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 16, 2018

Primary Completion Date

December 1, 2020

Study Completion Date

April 10, 2021

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

FOLFOXIRI Protocol

Triplet chemotherapy regimen consists from active three cytotoxic agents aiming to improve outcomes

Trial Locations (1)

11555

Kasr El AiniH, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT05316818 - Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma | Biotech Hunter | Biotech Hunter